Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · IEX Real-Time Price · USD
-0.038 (-6.97%)
Jul 19, 2024, 9:56 AM EDT - Market open

Company Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.

It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.

Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Evoke Pharma, Inc.
Evoke Pharma logo
Country United States
Founded 2007
IPO Date Sep 25, 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 4
CEO Matthew J. D'Onofrio MBA

Contact Details

420 Stevens Avenue, Suite 370
Solana Beach, California 92075
United States
Phone 858-345-1494
Website evokepharma.com

Stock Details

Ticker Symbol EVOK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001403708
CUSIP Number 30049G104
ISIN Number US30049G2030
Employer ID 20-8447886
SIC Code 2834

Key Executives

Name Position
Matthew J. D'Onofrio MBA Co-Founder, President, Chief Executive Officer, Chief Operating Officer, Secretary, Treasurer and Director
Dr. Marilyn R. Carlson D.M.D., M.D., RAC. Chief Medical Officer
Christopher Quesenberry Chief Commercial Officer - Gimoti (TM)

Latest SEC Filings

Date Type Title
Jun 20, 2024 8-K Current Report
Jun 7, 2024 8-K Current Report
May 28, 2024 8-K Current Report
May 15, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 14, 2024 ARS/A Filing
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
May 14, 2024 10-K/A [Amend] Annual report
May 14, 2024 8-K Current Report
Apr 10, 2024 ARS Filing